Arcturus Therapeutics (NASDAQ:ARCT) Given “Buy” Rating at HC Wainwright

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $60.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 153.59% from the stock’s previous close.

A number of other analysts also recently commented on ARCT. Canaccord Genuity Group cut their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a report on Friday, May 10th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.86.

Arcturus Therapeutics Stock Down 2.8 %

NASDAQ:ARCT opened at $23.66 on Tuesday. Arcturus Therapeutics has a one year low of $17.52 and a one year high of $45.00. The firm’s fifty day moving average is $30.12 and its two-hundred day moving average is $32.62.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) EPS for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. The company had revenue of $38.01 million during the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. Research analysts forecast that Arcturus Therapeutics will post -4.39 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 26,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the transaction, the chief operating officer now owns 447,448 shares of the company’s stock, valued at approximately $17,902,394.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in ARCT. Russell Investments Group Ltd. purchased a new position in Arcturus Therapeutics in the 1st quarter valued at approximately $40,000. AJOVista LLC purchased a new position in Arcturus Therapeutics in the 4th quarter valued at approximately $65,000. Quest Partners LLC purchased a new position in Arcturus Therapeutics in the 4th quarter valued at approximately $67,000. Public Employees Retirement System of Ohio purchased a new position in Arcturus Therapeutics in the 4th quarter valued at approximately $89,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in Arcturus Therapeutics by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,406 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.